Xeris Biopharma Holdings (XERS) Operating Income (2020 - 2026)

Xeris Biopharma Holdings has reported Operating Income for 7 years, with the latest figure at $7.9 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 356.18% year-over-year to $7.9 million; the trailing twelve-month figure through Mar 2026 stood at $35.9 million (up 259.63% YoY), and the FY2025 full-year result was $24.9 million, up 173.99% from the prior year.
• Operating Income for Q1 2026 stood at $7.9 million, down from $16.8 million in the prior quarter.
• The five-year high for Operating Income was $16.8 million in Q4 2025, with the low at -$29.1 million in Q1 2022.
• Historically, Operating Income has averaged -$7.5 million across 5 years, with a median of -$9.8 million in 2023.
• Annual changes were most pronounced in 2024 — Operating Income sank 162.43% — and 2025, when it soared 898.99%.
• Xeris Biopharma Holdings' Operating Income stood at -$15.2 million in 2022, then surged by 35.13% to -$9.8 million in 2023, then jumped by 117.06% to $1.7 million in 2024, then soared by 898.99% to $16.8 million in 2025, then plunged by 52.81% to $7.9 million in 2026.
• The last three Operating Income figures came in at $7.9 million (Q1 2026), $16.8 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.